692 related articles for article (PubMed ID: 8593782)
1. Characterization of a vitamin D3-resistant MCF-7 cell line.
Narvaez CJ; Vanweelden K; Byrne I; Welsh J
Endocrinology; 1996 Feb; 137(2):400-9. PubMed ID: 8593782
[TBL] [Abstract][Full Text] [Related]
2. Differential effects of 1,25-dihydroxyvitamin D3 and tetradecanoylphorbol acetate on cell cycle and apoptosis of MCF-7 cells and a vitamin D3-resistant variant.
Narvaez CJ; Welsh J
Endocrinology; 1997 Nov; 138(11):4690-8. PubMed ID: 9348195
[TBL] [Abstract][Full Text] [Related]
3. Induction of apoptosis in breast cancer cells in response to vitamin D and antiestrogens.
Welsh J
Biochem Cell Biol; 1994; 72(11-12):537-45. PubMed ID: 7654327
[TBL] [Abstract][Full Text] [Related]
4. 1,25-Dihydroxyvitamin D3 induces morphological and biochemical markers of apoptosis in MCF-7 breast cancer cells.
Simboli-Campbell M; Narvaez CJ; Tenniswood M; Welsh J
J Steroid Biochem Mol Biol; 1996 Jul; 58(4):367-76. PubMed ID: 8903420
[TBL] [Abstract][Full Text] [Related]
5. Interaction of two novel 14-epivitamin D3 analogs with vitamin D3 receptor-retinoid X receptor heterodimers on vitamin D3 responsive elements.
Verlinden L; Verstuyf A; Quack M; Van Camp M; Van Etten E; De Clercq P; Vandewalle M; Carlberg C; Bouillon R
J Bone Miner Res; 2001 Apr; 16(4):625-38. PubMed ID: 11315990
[TBL] [Abstract][Full Text] [Related]
6. Dissociation of vitamin D3 and anti-estrogen mediated growth regulation in MCF-7 breast cancer cells.
Nolan E; Donepudi M; VanWeelden K; Flanagan L; Welsh J
Mol Cell Biochem; 1998 Nov; 188(1-2):13-20. PubMed ID: 9823006
[TBL] [Abstract][Full Text] [Related]
7. Apoptotic regression of MCF-7 xenografts in nude mice treated with the vitamin D3 analog, EB1089.
VanWeelden K; Flanagan L; Binderup L; Tenniswood M; Welsh J
Endocrinology; 1998 Apr; 139(4):2102-10. PubMed ID: 9528999
[TBL] [Abstract][Full Text] [Related]
8. 1alpha,25-Dihydroxyvitamin D3 down-regulates estrogen receptor abundance and suppresses estrogen actions in MCF-7 human breast cancer cells.
Swami S; Krishnan AV; Feldman D
Clin Cancer Res; 2000 Aug; 6(8):3371-9. PubMed ID: 10955825
[TBL] [Abstract][Full Text] [Related]
9. Comparative effects of 1,25(OH)2D3 and EB1089 on cell cycle kinetics and apoptosis in MCF-7 breast cancer cells.
Simboli-Campbell M; Narvaez CJ; van Weelden K; Tenniswood M; Welsh J
Breast Cancer Res Treat; 1997 Jan; 42(1):31-41. PubMed ID: 9116316
[TBL] [Abstract][Full Text] [Related]
10. 20-Cyclopropyl-cholecalciferol vitamin D3 analogs: a unique class of potent inhibitors of proliferation of human prostate, breast and myeloid leukemia cell lines.
Koike M; Koshizuka K; Kawabata H; Yang R; Taub HE; Said J; Uskokovic M; Tsuruoka N; Koeffler HP
Anticancer Res; 1999; 19(3A):1689-97. PubMed ID: 10470102
[TBL] [Abstract][Full Text] [Related]
11. The anti-proliferative effects of 1alpha,25(OH)2D3 on breast and prostate cancer cells are associated with induction of BRCA1 gene expression.
Campbell MJ; Gombart AF; Kwok SH; Park S; Koeffler HP
Oncogene; 2000 Oct; 19(44):5091-7. PubMed ID: 11042697
[TBL] [Abstract][Full Text] [Related]
12. Vitamin D3 analogs and their 24-oxo metabolites equally inhibit clonal proliferation of a variety of cancer cells but have differing molecular effects.
Campbell MJ; Reddy GS; Koeffler HP
J Cell Biochem; 1997 Sep; 66(3):413-25. PubMed ID: 9257197
[TBL] [Abstract][Full Text] [Related]
13. 1,25-dihydroxyvitamin D3 induction of nerve growth factor in L929 mouse fibroblasts: effect of vitamin D receptor regulation and potency of vitamin D3 analogs.
Musiol IM; Feldman D
Endocrinology; 1997 Jan; 138(1):12-8. PubMed ID: 8977379
[TBL] [Abstract][Full Text] [Related]
14. Vitamin D and systemic cancer: is this relevant to malignant melanoma?
Osborne JE; Hutchinson PE
Br J Dermatol; 2002 Aug; 147(2):197-213. PubMed ID: 12174089
[TBL] [Abstract][Full Text] [Related]
15. Actions of vitamin D3, analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3.
Skowronski RJ; Peehl DM; Feldman D
Endocrinology; 1995 Jan; 136(1):20-6. PubMed ID: 7530193
[TBL] [Abstract][Full Text] [Related]
16. Antiestrogen potentiation of antiproliferative effects of vitamin D3 analogues in breast cancer cells.
Love-Schimenti CD; Gibson DF; Ratnam AV; Bikle DD
Cancer Res; 1996 Jun; 56(12):2789-94. PubMed ID: 8665515
[TBL] [Abstract][Full Text] [Related]
17. Thyroid hormone receptor does not heterodimerize with the vitamin D receptor but represses vitamin D receptor-mediated transactivation.
Raval-Pandya M; Freedman LP; Li H; Christakos S
Mol Endocrinol; 1998 Sep; 12(9):1367-79. PubMed ID: 9731705
[TBL] [Abstract][Full Text] [Related]
18. MART-10, a less calcemic vitamin D analog, is more potent than 1α,25-dihydroxyvitamin D3 in inhibiting the metastatic potential of MCF-7 breast cancer cells in vitro.
Chiang KC; Chen SC; Yeh CN; Pang JH; Shen SC; Hsu JT; Liu YY; Chen LW; Kuo SF; Takano M; Kittaka A; Sun CC; Juang HH; Chen TC
J Steroid Biochem Mol Biol; 2014 Jan; 139():54-60. PubMed ID: 24125734
[TBL] [Abstract][Full Text] [Related]
19. Lipopolysaccharide negatively modulates vitamin D action by down-regulating expression of vitamin D-induced VDR in human monocytic THP-1 cells.
Pramanik R; Asplin JR; Lindeman C; Favus MJ; Bai S; Coe FL
Cell Immunol; 2004; 232(1-2):137-43. PubMed ID: 15876428
[TBL] [Abstract][Full Text] [Related]
20. Regulation of gene Expression by 1alpha,25-dihydroxyvitamin D3 and Its analog EB1089 under growth-inhibitory conditions in squamous carcinoma Cells.
Akutsu N; Lin R; Bastien Y; Bestawros A; Enepekides DJ; Black MJ; White JH
Mol Endocrinol; 2001 Jul; 15(7):1127-39. PubMed ID: 11435613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
